Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia

Biological Psychiatry

Volumn 50, Issue 10, 2001, Pages 729-742

  Konradi, Christine ^a,b,c   Heckers, Stephan ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Clozapine; Gene expression; Haloperidol; Neuroplasticity; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

BRAIN SIZE; CONCENTRATION RESPONSE; CORPUS STRIATUM; DRUG MECHANISM; GENE EXPRESSION; HUMAN; MORPHOLOGY; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SCHIZOPHRENIA; SYNAPSE;

ANTIPSYCHOTIC AGENTS; BRAIN; CORPUS STRIATUM; HALOPERIDOL; HUMANS; NEURONAL PLASTICITY; NUCLEUS ACCUMBENS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0035890854     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01267-7     Document Type: Review

References (167)

1. Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice
2. Assembly of presynaptic active zones from cytoplasmic transport packets
3. Altered distribution of nicotinamide-adenine dinucleotide phosphate- diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development
4. Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion
5. Neurotrophins and depression
6. Anterograde transport of brain-derived neurotrophic factor and its role in the brain
7. Symptoms, signs, and diagnosis of schizophrenia
8. Pieces of the schizophrenia puzzle fall into place
9. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?
10. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration
11. Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs
12. No-new-neurons dogma loses ground
13. The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics
14. Emerging principles of altered neural circuitry in schizophrenia
15. The effects of haloperidol on synaptic patterns in the rat striatum
16. Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats
17. Haloperidol-induced plasticity of axon terminals in rat substantia nigra
18. Cerebral morphometry and clozapine treatment in schizophrenia
19. The temporolimbic system theory of positive schizophrenic symptoms
20. Expression of messenger RNAs encoding ionotropic glutamate receptors in rat brain: Regulation by haloperidol
21. Caudate nucleus morphology in tardive dyskinesia
22. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics
23. Neuroleptic medications inhibit complex I of the electron transport chain
24. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain
25. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats
26. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro
27. Stem cells and neurogenesis in the adult brain
28. Schizophrenia
29. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine
30. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs
31. Striatal enlargement in rats chronically treated with neuroleptic
32. The glutamatergic dysfunction hypothesis for schizophrenia
33. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
34. Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment
35. Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex
36. The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains
37. Protein synthesis and memory: A review
38. Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus
39. Chronic haloperidol treatment impairs glutamate transport in the rat striatum
40. Brain morphology in first-episode schizophrenic-like psychotic patients: A quantitative magnetic resonance imaging study
41. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization
42. Neuroleptic treatment and caudate plasticity
43. Developmental regulation of spine motility in the mammalian central nervous system
44. Striatal synaptophysin expression and haloperidol-induced synaptic plasticity
45. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia
46. Synaptophysin gene expression in schizophrenia. Investigation of synaptic pathology in the cerebral cortex
47. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography
48. Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes
49. The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain
50. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias
51. Basal ganglia pathology in schizophrenia and tardive dyskinesia: An MRI quantitative study
52. Dendritic spine changes associated with hippocampal long-term synaptic plasticity
53. Neurogenesis in the adult human hippocampus
54. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects
55. Long-lasting morphological changes in dendritic spines of dentate granular cells following stimulation of the entorhinal area
56. Rapid actin-based plasticity in dendritic spines
57. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs
58. The missing link: A failure of fronto-hippocampal integration in schizophrenia
59. Dopamine receptor subtypes: Differential regulation after 8 months treatment with antipsychotic drugs
60. CREB: A mediator of long-term memory from mollusks to mammals
61. Assembly of new individual excitatory synapses: Time course and temporal order of synaptic molecular recruitment
62. The disconnection hypothesis
63. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity
64. Tardive dyskinesia and substrates of energy metabolism in CSF
65. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133
66. Hippocampal neurogenesis in adult Old World primates
67. Regulation of ion channels by cAMP-dependent protein kinase and A-kinase anchoring proteins
68. What are the functional consequences of neurocognitive deficits in schizophrenia?
69. Synaptic vesicle phosphoproteins and regulation of synaptic function
70. Neurogenesis in the adult brain: Death of a dogma
71. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia
72. Prefabrication provides synapses on demand
73. Synaptic adhesion: The building blocks of memory?
74. Structure, development, and plasticity of dendritic spines
75. The neuropathological effects of antipsychotic drugs
76. From contact to connection: Early events during synaptogenesis
77. Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems
78. Cortex, white matter, and basal ganglia in schizophrenia: A volumetric postmortem study
79. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia
80. Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum
81. Synapse elimination and plasticity in developing human cerebral cortex
82. Synaptogenesis in human visual cortex-evidence for synapse elimination during normal development
83. Initiation and adaptation: A paradigm for understanding psychotropic drug action
84. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia
85. An analysis of contemporary morphological concepts of synaptic remodelling in the CNS: Perforated synapses revisited
86. Filopodia, spines, and the generation of synaptic diversity
87. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
88. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: A possible neurochemical basis for 'hypofrontality'
89. Synaptic plasticity in the rat striatum following chronic haloperidol treatment
90. Changes in caudate volume with neuroleptic treatment
91. Slices have more synapses than perfusion-fixed hippocampus from both young and mature rats
92. The effects of haloperidol on synaptic plasticity in rat's medial prefrontal cortex
93. Haloperidol-induced Fos expression in striatum is dependent upon transcription factor cyclic AMP response element binding protein
94. The cAMP-response-element-binding protein interacts, but Fos protein does not interact, with the proenkephalin enhancer in rat striatum
95. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms
96. Synaptic changes in the striatum of schizophrenic cases: A controlled postmortem ultrastructural study
97. Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia
98. The human striatum in schizophrenia. I. Increase in overall relative striatal volume in schizophrenics
99. Development of neuron-neuron synapses
100. Intracellular modulation of NMDA receptor function by antipsychotic drugs
101. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: Effects of chronic treatment with typical and atypical antipsychotic drugs
102. Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents
103. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja
104. Differential expression of inducible transcription factors in basal ganglia neurons
105. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
106. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity
107. Antipsychotic drug actions: A clue to the neuropathology of schizophrenia?
108. Postsynaptic actin and neuronal plasticity
109. Neurotrophins and synaptic plasticity
110. Schizophrenia as a disorder of developmentally reduced synaptic connectivity
111. Expression of the proneurotensin gene in the rat brain and its regulation by antipsychotic drugs
112. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions
113. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol
114. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment
115. Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex
116. Haloperidol-induced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and glutamate immunoreactivity
117. MRI abnormalities in tardive dyskinesia
118. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex
119. Depolarization inactivation of dopamine neurons: Terminal release characteristics
120. Transcriptional regulation by cyclic AMP
121. Effect of chronic haloperidol treatment on synaptic protein mRNAs in the rat brain
122. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine
123. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments
124. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients
125. New neurons extraordinary evidence or extraordinary conclusion?
126. NMDA receptor hypofunction model of schizophrenia
127. Comparative effects of dopamine D(1) and D(2) receptor antagonists on nerve growth factor protein induction
128. Comparison of the effects of dopamine D1 and D2 receptor antagonists on nerve growth factor mRNA expression
129. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia
130. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs
131. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum
132. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine
133. Effects of olanzapine on regional C-Fos expression in rat forebrain
134. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity
135. Dopamine induces neurite retraction in retinal horizontal cells via diacylglycerol and protein kinase C
136. In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus
137. Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum
138. Protein phosphorylation in neuronal plasticity and gene expression
139. Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment
140. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats
141. Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats
142. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors
143. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons
144. The reduced neuropil hypothesis: A circuit based model of schizophrenia
145. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation
146. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task
147. CREB and memory
148. Regulation of excitatory and inhibitory neurotransmitter-gated ion channels by protein phosphorylation
149. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors
150. Direct measurement of coupling between dendritic spines and shafts
151. Subcortical and temporal structures in affective disorder and schizophrenia: A magnetic resonance imaging study
152. Regulation of ligand-gated ion channels by protein phosphorylation
153. Glutamatergic aspects of schizophrenia
154. Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks
155. LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite
156. Binding of antipsychotic drugs to cortical 5-HT2A receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients
157. Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment
158. Contrasting effects of chronic clozapine, Seroquel(TM) (ICI 204,636) and haloperidol administration of deltaFosB-like immunoreactivity in the rodent forebrain
159. Swelling of dendritic spines in the fascia dentata after stimulation of the perforant fibers as a mechanism of post-tetanic potentiation
160. Evidence for ultrastructural changes in cortical axodendritic synapses following long-term treatment with haloperidol or clozapine
161. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain
162. Rapid dendritic movements during synapse formation and rearrangement
163. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia
164. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism
165. Maturation of a central glutamatergic synapse
166. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations
167. Evidence for a role of dendritic filopodia in synaptogenesis and spine formation